{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:36:39Z","timestamp":1788572199630,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40262-024-01399-8","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:18:56Z","timestamp":1721143136000},"page":"1045-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort"],"prefix":"10.1007","volume":"63","author":[{"given":"Marinda","family":"Meertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline L.","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud B. A.","family":"van der Kleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Westerdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels A. D.","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos F.","family":"Bleckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rieborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex L. T","family":"Imholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Martin","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelie","family":"Vulink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Esther","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M. E.","family":"Desar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Dutch Pharmacology Oncology Group (DPOG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"11","key":"1399_CR1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32(11):1348\u201365.","journal-title":"Ann Oncol"},{"issue":"7","key":"1399_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(7):815\u201333.","journal-title":"J Natl Compr Cancer Netw."},{"issue":"9829","key":"1399_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"key":"1399_CR4","unstructured":"European Medicines Agency. Summary of product characteristics Vortrient 200 and 400 mg film-coated tablets. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/votrient. Cited 15 Aug 2023."},{"issue":"2","key":"1399_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.14185","volume":"86","author":"K Westerdijk","year":"2020","unstructured":"Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP, Dutch P, Oncology G. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86(2):258\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1399_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40262-016-0443-y","volume":"56","author":"H Yu","year":"2017","unstructured":"Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, et al. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet. 2017;56(3):293\u2013303.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909\u201316.","journal-title":"Br J Cancer"},{"issue":"6","key":"1399_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","volume":"80","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol. 2017;80(6):1171\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"1399_CR9","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","volume":"24","author":"CN Sternberg","year":"2018","unstructured":"Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res. 2018;24(13):3005\u201313.","journal-title":"Clin Cancer Res"},{"key":"1399_CR10","doi-asserted-by":"crossref","unstructured":"Minot-This MS, Boudou-Rouquette P, Jouinot A, de Percin S, Balakirouchenane D, Khoudour N, et al. Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients. Pharmaceutics. 2022;14(6).","DOI":"10.3390\/pharmaceutics14061224"},{"key":"1399_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","volume":"10","author":"SL Groenland","year":"2022","unstructured":"Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes D, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;10:1071\u201382.","journal-title":"Ann Oncol"},{"issue":"5","key":"1399_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","volume":"41","author":"SL Groenland","year":"2019","unstructured":"Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes D, Desar IME, et al. Therapeutic drug monitoring of oral anticancer drugs: the Dutch Pharmacology Oncology Group-therapeutic drug monitoring protocol for a prospective study. Ther Drug Monit. 2019;41(5):561\u20137.","journal-title":"Ther Drug Monit"},{"key":"1399_CR13","unstructured":"Dutch Cancer Society. Implementatie van ge\u00efndividualiseerd doseren van orale doelgerichte therapie bij de behandeling van kanker 2019. https:\/\/www.kwf.nl\/onderzoek\/onderzoeksdatabase\/implementatie-van-geindividualiseerd-doseren-van-orale-doelgerichte. Cited 12 July 2023."},{"issue":"5","key":"1399_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/cpt.1515","volume":"106","author":"FJE Lubberman","year":"2019","unstructured":"Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, et al. The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET Study). Clin Pharmacol Ther. 2019;106(5):1076\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1399_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bcp.15918","volume":"90","author":"EL Giraud","year":"2024","unstructured":"Giraud EL, Te Brake LMH, van den Hombergh ECA, Desar IME, Kweekel DM, van Erp NP. Results of the first international quality control programme for oral targeted oncolytics. Br J Clin Pharmacol. 2024;90(1):336\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1399_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","volume":"31","author":"Y Wang","year":"2009","unstructured":"Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31(5):579\u201384.","journal-title":"Ther Drug Monit"},{"key":"1399_CR17","unstructured":"R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2021. https:\/\/www.r-project.org\/."},{"issue":"20","key":"1399_CR18","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1158\/1078-0432.CCR-17-1873","volume":"23","author":"A Bellesoeur","year":"2017","unstructured":"Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, et al. Individualized pazopanib dosing-letter. Clin Cancer Res. 2017;23(20):6377.","journal-title":"Clin Cancer Res"},{"key":"1399_CR19","unstructured":"Food and Drug Administration. Project optimus\u2014reforming the dose optimization and dose selection paradigm in oncology. 2023. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Cited 1 Nov 2023."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01399-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:13:47Z","timestamp":1721492027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01399-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01399-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"24 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TUNE project (Grant no. 11575) was funded by the Dutch Cancer Society (KWF Kankerbestrijding). In addition, the DPOG-TDM study was supported by unrestricted research grants from Ipsen, Merck, Novartis, Pfizer, and Roche. They had no involvement in any other aspect of this study. A research grant for the Dutch GIST Registry was received from Novartis, Pfizer, Bayerv and Deciphera. These funding resources were not involved in the conduct of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MM, ELG, MBAvdK, KW, NADG, RFB, AR, ALTI, H-MO, AV, ML, PH, SLWK, DJARM, KEB, DJT, ADRH, and IMED declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. WTAvdG reports institutional research fees paid to the institute from Lilly and advisory compensation from Springworks, PTC Therapeutics, and Agenus, all outside the submitted work. RHJM reports research funding paid to the institute from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Deuter Oncology, Nordic Pharma, Novartis, Pamgene, Pfizer, Roche, Sanofi, and Servier, all outside the submitted work. HG reports institutional research funding from Daiichi Sankyo, Deciphera Pharmaceuticals, Ipsen, and Novartis. ADRH is an Editorial Board member of <i>Clinical Pharmacokinetics<\/i>. ADRH was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. NPvE reports research funding paid to the institute from Astellas and Ipsen, all outside the submitted work. NS reports research grants paid to the institute from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, and Takeda, all outside the submitted work. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, and Luszana.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The DPOG-TDM study (METC17.0941; 07-08-2017) and the TUNE study (2019-5402; 09-05-2019) were approved by the institutional review boards of the NKI-AVL and the RUMC, respectively, as well as the collection of data from patients included in routine clinical care in the NKI-AVL. Approval from the board of directors of each individual hospital was obtained for all participating centers. The local institutional review boards of both the NKI-AVL and the RUMC approved data collection and sharing (14290_IRBd22-206; 25-01-2023).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The data generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"MM and ELG wrote the manuscript; MM, ELG, ADRH, NPvE, IMED, and NS designed the research; MM and ELG performed the research; MM and ELG analyzed the data; MBAvdK, KW, NADG, RFB, AR, ALTI, H-MO, AV, ML, PH, WTAvdG, HG, DJARM, KEB, DJT, SLWK, and RHJM were responsible for critical revision of the manuscript. All authors gave final approval of the version to be submitted.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"All patients provided written informed consent.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provide this consent.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The codes used for analyses in the current study are available from the corresponding author on reasonable request.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}